CSL Limited (CSL)

CSL is a leading global biotechnology company with a portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza.

Established in 1916, CSL is driven by the promise to save lives using the latest technologies. Today, CSL – including its two businesses, CSL Behring and Seqirus – provides life-saving products to more than 60 countries and employs nearly 20,0000 people.

CSL has a significant R&D presence in Australia, led from the company’s main campus in the Melbourne Biomedical Precinct which is home to its corporate head office as well as housing significant manufacturing facilities. The company’s global hub for Early Research and Translational Medicine is based as The University of Melbourne’s Bio21 Institute in the Melbourne Biomedical Precinct.

For more information, visit the CSL website here